MedTrace Logo

Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1603-1 and NVP-1603-2

NCT03220399 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2019-08-26

No results posted yet for this study

Summary

The purpose of this study is to compare the pharmacokinetics and safety/tolerability between NVP-1603-1 and NVP-1603-2

Conditions

  • Healthy

Interventions

DRUG

NVP-1603-1 (P)

1capsule, single oral dosing

DRUG

NVP-1603-2 (T)

1tablet, single oral dosing

DRUG

NVP-1603-1 and NVP-1603-2 (P+T)

1capsule and 1tablet co-administration, oral single dosing

Sponsors & Collaborators

  • NVP Healthcare

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2020-03-28
Completion
2020-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03220399 on ClinicalTrials.gov